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The considerable burden of childhood cancer, in terms of both
morbidity and mortality, has generated extensive aetiological
research over recent decades. Despite these efforts, apart from
ionizing radiation, the causes of childhood leukaemia and other
malignancies remain largely unexplained (Doll, 1989). The identi-
fication of risk factors has frequently focused on the vulnerable
period of intrauterine growth and development, birth and neonatal
life. The population-based Scottish case control study of child-
hood leukaemia and cancer has investigated potential risk factors
occurring in the prenatal and perinatal period based on data
abstracted from the hospital records of both mothers and neonates.
A key aspect was to test prior hypotheses as well as identify asso-
ciations for separate diagnostic subgroups and search for patterns
of risk within and across distinct subsets of childhood malignancy.
SUBJECTS AND METHODS
The cases studied were children (0–14 years) diagnosed with
leukaemia or another malignancy during 1991–1994 while living
in Scotland. The childhood population of Scotland at the 1991
census was 959 268. Pathological confirmation of diagnosis was
required and cross-checks with the Scottish Cancer Registry and
the UK National Register of Childhood Cancers (Stiller, 1995)
optimized completeness of case ascertainment. Population-based
controls matched on age (to within one calendar month), sex and
health board area of residence were randomly selected from all
eligible children registered for primary care. This sampling frame
is considered appropriate representation of the general population
in this age group (Roberts et al, 1995). An optimum two controls
per case were selected and a full description of the study method-
ology is published elsewhere (McKinney et al, 1995). Scotland is a
participating centre in the UK Children’s Cancer Study (UKCCS).
The study was approved by the Local Research Ethics
Committees of the 15 Health Boards in Scotland. Consultant clini-
cians or general practitioners gave consent to approach and inter-
view mothers who gave their signed permission for information to
be abstracted from their medical notes. In Scotland, 76 hospitals
and maternity units gave access to medical records relating to
births from 1976 to 1994. Records for births occurring in England
and Wales (3.4%) were obtained by post.
Information from obstetric, delivery and neonatal records was
recorded by two trained abstractors onto a specifically designed
and highly structured standard form which has been validated in a
previous study (Roman et al, 1997). Consistency and data quality
were maximized through a programme of continual monitoring,
coding checks and duplicate abstractions by the senior midwife
abstractor (EF).
Demographic details of the mother were collected at interview.
Each child was assigned a deprivation score (five categories repre-
senting quintiles of the Scottish population) according to Carstairs
and Morris (1991) from the home address at the time of birth and
its validated postcode. This was based on 1981 census data for pre-
1986 births and the 1991 census thereafter. Illnesses were coded
according to the 10th edition of the International Classification of
Diseases (WHO, 1994) and the drug codes were classified using
groups within the British National Formulary (British National
Formulary, 1992).
The Birch and Marsden classification (Birch and Marsden,
1987) was used to define the following diagnostic subsets of cases
– leukaemias, lymphomas, central nervous system (CNS) tumours
and other solid tumours (neuroblastomas, retinoblastomas, renal,
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hepatic, bone and germ cell tumours, soft tissue sarcomas and
carcinomas) and a subset of the leukaemias, acute lymphoblastic
leukaemia (ALL).
A profile of the study sample showing the original eligible cases
and controls and the proportion of those who were interviewed,
along with the proportion of interviewed subjects participating in
Table 1 Odds ratios (OR), 95% confidence intervals (CI) and numbers of exposed cases (ca) and controls (co) for demographic risk factors by diagnostic
subgroup
Mother Categorya Total Acute lymphoblastic Other solid
leukaemias leukaemia (subset) Lymphomas CNS tumours tumours
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Ca 144, Co 271 Ca 124, Co 236 Ca 45, Co 82 Ca 75, Co 133 Ca 126, Co 230
School leaving age (years) ≤ 16 vs > 16 0.77 (0.45–1.29) 0.92 (0.53–1.60) 1.40 (0.63–3.14) 0.61 (0.30–1.25) 0.75 (0.46–1.21)
36, 77 33, 64 17, 25 14, 35 34, 72
Educational qualifications None vs some 1.18 (0.73–1.91) 1.22 (0.73–2.02) 0.52 (0.22–1.26) 0.73 (0.39–1.36) 0.59b (0.37–0.94)
100, 180 86, 155 27, 59 47, 92 73, 161
Deprivation index at birth l – least deprived 1.00 1.00 1.00 1.00 1.00
24, 50 18, 45 8, 11 12, 17 16, 29
II 0.92 (0.46–1.83) 1.31 (0.62–2.76) 1.01 (0.28–3.60) 0.23 (0.06–0.86) 0.89 (0.38–2.10)
24, 53 23, 43 10, 13 7, 31 23, 40
III 1.27 (0.64–2.48) 1.38 (0.66–2.85) 0.79 (0.21–3.00) 0.96 (0.35–2.60) 1.11 (0.47–2.67)
30, 48 25, 44 9, 17 18, 23 23, 38
IV 1.03 (0.53–2.03) 1.32 (0.63–2.75) 0.54 (0.13–2.25) 0.79(0.26–2.38) 0.86 (0.36–2.02)
27, 53 24, 44 5, 14 13, 25 24, 46
V – most deprived 1.18 (0.56–2.49) 1.35 (0.60–3.03) 0.53 (0.14–1.96) 0.79 (0.28–2.24) 0.77 (0.34–1.73)
33, 60 28, 54 8, 17 18, 30 30, 63
Ethnic group White vs non-white 1.00 (0.36–2.80) 1.10 (0.38–3.16) – – –
6, 11 6, 10 2, 4 1, 1 3, 5
aReference category stated first. bP = 0.027.
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Figure 1 Frequency of case and control interviews and obstetric abstractions. 1Incomplete at end of study period. 2Exclusions: Down’s syndrome, multiple
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the obstetric data study, is shown in Figure 1. The other solid
tumour group comprises 33 neuroblastomas, seven retinoblast-
omas, 23 renal, three hepatic, 13 bone and 23 germ cell tumours,
13 soft tissue sarcomas and 11 carcinomas and other cancers.
Further details of the numbers of case and control mothers inter-
viewed and response rates are published elsewhere (McKinney et
al, 1998).
The statistical analysis excluded cases diagnosed under 3
months (n = 16), with Down’s syndrome (n = 5) or from a multiple
birth (n = 12) which resulted in the loss of 33 cases and their 43
matched controls. In addition, as the analysis was restricted to
matched sets, information was lost for a further 17 cases (4%)
lacking controls and 43 controls (5%) without a matched case.
These were distributed equally across the diagnosis groups. A
standard case control analysis (Breslow and Day, 1980) of 390
matched case control sets (326 triplets, 64 pairs) was performed
using Stata (StataCorp, 1997). Odds ratios (OR), 95% confidence
intervals (CI) and P-values were estimated using conditional
logistic regression. The presentation of ORs is restricted to when
the prevalence of an exposure was at least 5% in either cases or
controls. When appropriate and unless otherwise stated, missing
values were included in the reference category.
RESULTS
Table 1 shows results for demographic factors. There was a reduc-
tion in the risk of CNS tumours and other solid tumours, the latter
reaching statistical significance, both with increased levels of
education and school-leaving age; the children of mothers who
were more highly educated were at lower risk. There was no
evidence of any trend in risk of any of the malignancies studied in
relation to levels of deprivation.
Results for pregnancy-related factors are shown in Table 2. The
only statistically significant risks were a positive association with
infections during pregnancy for the other solid tumours and an OR
< 1 for the lymphomas with ultrasound examinations. The infec-
tions were accounted for by respiratory tract infections, of which
the majority (5/8 cases) occurred in the third trimester. There was
no association of risk with increasing age of mother in any
subgroup. Drugs ingested during pregnancy (Table 3) reflected the
Table 2 Odds ratios (OR), 95% confidence intervals (CI) and numbers of exposed cases (ca) and controls (co) for maternal pregnancy related risk factors by
diagnostic subgroup
Factor Categorya Total Acute lymphoblastic Lymphomas CNS tumours Other solid
leukaemias leukaemia (subset) tumours
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Ca 144, Co 271 Ca 124, Co 236 Ca 45, Co 82 Ca 75, Co 133 Ca 26, Co 230
Mother’s age at birth ≤19 1.86 (0.84–4.10) 1.63 (0.69–3.85) 3.14 (0.76–13.0) 1.73 (0.49–6.10) 0.85 (0.40–1.80)
(years) 14, 15 11, 14 6, 5 6, 7 10, 23
20–34 1.00 1.00 1.00 1.00 1.00
120, 234 104, 204 36, 75 65, 114 108, 185
³35 0.90 (0.41–1.95) 0.98 (0.43–2.24) 2.30 (0.38–14.1) 0.60 (0.19–1.92) 0.66 (0.28–1.55)
10, 22 9, 18 3, 2 4, 12 8, 22
Parity 0 vs 1 or more 0.82 (0.55–1.23) 0.81 (0.52–1.25) 1.11 (0.51–2.39) 0.88 (0.50–1.55) 1.19 (0.78–1.81)
72, 148 61, 127 29, 51 40, 77 71, 119
Gravidity 1 vs more than 1 1.01 (0.67–1.51) 0.95 (0.62–1.47) 1.05 (0.49–2.27) 1.20 (0.66–2.18) 0.95 (0.61–1.48)
87, 162 73, 140 29, 52 49, 84 77, 144
Prior miscarriage No vs yes 1.28 (0.68–2.40) 1.09 (0.54–2.17) 0.26 (0.03–2.10) 1.71 (0.66–4.44) 0.51 (0.23–1.11)
17, 26 13, 23 1, 7 8, 9 9, 29
Infections: Any None vs 1 or more 1.43 (0.85–2.42) 1.44 (0.81–2.55) 0.82 (0.28–2.41) 0.64 (0.30–1.34) 1.81b (1.07–3.06)
33, 46 26, 36 5, 12 13, 31 30, 32
:Respiratory tract None vs 1 or more 1.46 (0.58–3.67) 1.64 (0.60–4.46) – 0.38 (0.08–1.97) 14.1c (1.76–113.7)
9, 12 8, 10 1, 3 2, 9 8, 1
:Viral None vs 1 or more – – – – –
5, 8 4, 8 0, 1 0, 1 2, 3
:Genitourinary None vs 1 or more 1.36 (0.66–2.83) 1.18 (0.50–2.79) 1.50 (0.34–6.70) 0.91 (0.38–2.18) 2.20 (0.95–5.08)
13, 18 9, 14 3, 4 8, 14 13, 11
:Fungal None vs 1 or more – – – – –
2, 13 2, 11 1, 2 2, 4 5, 8
Pre-eclampsia No vs yes 1.09 (0.66–1.82) 1.19 (0.69–2.05) 0.53 (0.19–1.51) 0.77 (0.38–1.54) 1.05 (0.61–1.82)
34, 57 28, 45 6, 17 16, 34 26, 46
Excessive vomiting No vs yes 0.49 (0.17–1.43) 0.42 (0.13–1.35) 0.64 (0.10–4.16) 1.25 (0.46–3.43) 0.92 (0.33–2.52)
5, 17 4, 16 2, 5 7, 10 6, 12
Ultrasound scans None vs 1 or more 1.07 (0.57–1.99) 1.08 (0.56–2.09) 0.32d (0.11–0.92) 2.47 (0.86–7.08) 2.01 (0.98–4.12)
121, 228 104, 198 28, 65 69, 112 114, 192
Abdominal X-rays None vs 1 or more 2.26 (0.69–7.45) 2.50 (0.67–9.31) 0.71 (0.17–2.97) 1.11 (0.24–5.05) 1.20 (0.29–5.02)
6, 5 5, 4 3, 7 3, 4 3, 5
Mode of delivery Normal 1.00 1.00 1.00 1.00 1.00
100, 98 84, 169 33, 59 59, 94 92, 163
Assisted 1.05 (0.58–1.91) 1.06 (0.56–2.00) 0.89 (0.28–2.91) 0.59 (0.24–1.45) 0.61 (0.31–1.18)
20, 38 18, 34 5, 11 8, 21 14, 41
Caesarean 1.43 (0.79–2.59) 1.43 (0.77–2.67) 1.03 (0.36–3.01) 0.68 (0.27–1.72) 1.35 (0.71–2.57)
24, 35 22, 33 7, 12 8, 18 20, 26
aReference category stated first; bP = 0.028; cP = 0.013; dP = 0.034.Perinatal risks for childhood leukaemia and cancer 1847
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observed increase in the risk of infections for the solid tumour
group with a raised risk for antibiotics. An inverse association was
observed for use of topical antifungals in the leukaemias and ALL
groups, although the OR was not statistically significant for the
ALLs. Adjustment for maternal age, which is potentially associ-
ated with increased attendance at hospital, showed no evidence of
confounding this result.
For drugs taken in labour (not tabulated), which included anal-
gesia, there were no significantly positive or negative ORs with
the exception of a reduced risk for antacid use for the CNS
tumours (cases 14, controls 39, OR 0.33, 95% CI 0.13–0.89).
Neonatal risk factors are presented in Table 4. A significantly
reduced risk for neonatal infections is observed for ALL,
accounted for by ‘skin infections’ which mainly comprise
omphalitis or infection of the umbilical cord. For ALL, 15 (12.1%)
cases and 52 (22.0%) controls were recorded with ‘any infection’
and two (1.6%) cases and 19 (8.1%) controls with ‘skin infec-
tions’. For ‘any infection’ in the ALLs, 7/15 (47%) cases and
24/52 (46%) were confirmed by positive swab test results.
Separate adjustment of the significant OR for ‘any infection’ and
skin infections by the other significant associated variables, Apgar
scores and birth asphyxiation had no effect on the magnitude or
significance of the OR. Adjusting by deprivation score (five cate-
gories) and maternal school leaving age (< 16 vs 16 or older), on
the grounds that the occurrence of leukaemia may be influenced
by social class, had little effect on the significance or magnitude of
the OR. The appearance of neonatal infections may be related to
mode of delivery with fewer infections expected for caesarean
deliveries. Adjustment for mode of delivery did not affect any
neonatal infections results for the leukaemia group. The risk of
skin infections is significantly raised for the ‘other solid tumours’
with 6/14 cases being diagnosed with Wilm’s tumour.
Two linked exposures, poor Apgar scores (4–6) at 1 min, and
birth asphyxia (ICD-10 P21), had significantly raised OR for the
leukaemias and ALLs, except for Apgars 4–6 for the ALLs which
only approached significance (see Table 4). Proportions of cases
and controls exposed for leukaemias were: Apgars 4–6 cases
18.8%, controls 11.1%; birth asphyxia cases 11.1%, controls
4.8%; and correspondingly for ALL cases 19.4%, controls 11.4%
and cases 10.5%, controls 4.7% respectively. At 5 min, no children
had an Apgar score of 3 or less and for 4–6 the OR was close to
unity and non-significant.
Table 5 shows details of infectious exposure in the leukaemias.
For all infections taken together, the protective effect is seen to be
significant in the 0 to 4-year-old ALLs, but not in those aged 5–14
years. The high proportion of exposed controls in the 0 to 4-years-
olds (25.3%) compared to the 5–14 group (16.3%) was reversed
for the CNS tumours (0–4, 14.0%; 5–14, 19.3%), reduced for the
‘other solid tumours’ (0–4, 21.1%; 5–14, 15.9%) and similar for
the smaller group of lymphomas (0–4, 23.8%; 5–14, 16.4%).
DISCUSSION
A key strength of the population-based Scottish case control study
was the use of medical records as the principal source of informa-
tion thus avoiding reliance on self-reporting of illness, which is
particularly susceptible to recall bias. A very high proportion of
notes were abstracted both for case and control mothers, despite
elapsed times of up to 20 years between birth and data collection.
Data abstraction was restricted to two trained researchers, one
of whom was a midwife. Although not blind to case control status,
the abstractors had no knowledge of the case diagnosis and were
unaware of the hypotheses under investigation. The use of a
specifically designed highly structured and previously validated
data collection form (Roman et al, 1997) reduced the likelihood of
systematic bias. The method of analysis was conservative, using
only matched sets, resulting in the loss of a small amount of data,
but this was proportionately distributed between the cases and
controls and across diagnostic groups.
The entire study was designed to collect interview data along
with further independent sets of information from obstetric and
general practitioner records. Recruitment into the interview phase
of the study may have been subject to bias as the refusal rate for
eligible cases was 6% compared to 26% for controls. However,
Table 3 Odds ratios (OR), 95% confidence intervals (CI) and numbers of exposed cases (ca) and controls (co) for drugs taken in pregnancy
Total Acute lymphoblastic Other solid
leukaemias leukaemia (subset) Lymphomas CNS tumours tumours
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
(Ca 144, Co 271) (Ca 124, Co 236) (Ca 45, Co 82) (Ca 75, Co 133) (Ca 126, Co 230)
Antacids 1.15 (0.52–2.55) 1.24 (0.50–3.06) 1.11 (0.24–5.20) 1.27 (0.39–4.14) 0.97 (0.42–2.22)
11, 17 9, 13 3, 5 6, 9 9, 17
Hypnotics and anxiolytics 1.45 (0.67–3.14) 2.04 (0.88–4.74) 0.43 (0.11–1.63) 1.36 (0.57–3.24) 0.88 (0.41–1.90)
13, 17 13, 13 3, 12 9, 12 11, 23
Analgesics 1.33 (0.68–2.62) 1.30 (0.60–2.82) 0.58 (0.14–2.35) 0.86 (0.29–2.55) 0.97 (0.45–2.11)
15, 21 11, 16 3, 9 5, 10 12, 24
Antibiotics 1.60 (0.92–2.80) 1.74 (0.95–3.20) 0.75 (0.20–2.83) 0.65 (0.28–1.46) 2.16b (1.10–4.25)
26, 34 23, 28 3, 8 9, 23 21, 19
Topical anti-fungals 0.10a (0.01–0.75) 0.14 (0.02–1.09) 1.00 (0.25–4.00) 0.74 (0.24–2.23) 1.74 (0.82–3.68)
1, 18 1, 14 3, 6 5, 12 14, 15
Iron preparations 0.95 (0.62–1.45) 0.80 (0.51–1.25) 0.79 (0.36–1.73) 0.89 (0.51–1.58) 1.03 (0.66–1.60)
75, 143 57, 120 20, 41 39, 75 70, 129
Anti-nauseants – – 1.88 (0.39–8.92) – 2.02 (0.67–6.12)
6, 4 4, 2 4, 5 2, 1 7, 7
General anaesthetics – – – – –
4, 2 4, 2 0, 1 3, 0 2, 0
aP = 0.025; bP = 0.026.1848 PA McKinney et al
British Journal of Cancer (1999) 80(11), 1844–1851 © 1999 Cancer Research Campaign 
66% of the controls were the ‘first choice’ mothers to be inter-
viewed and the geographical pattern and age distribution of the
refusers did not differ between cases and controls.
The testing of case control differences in over 200 variables,
resulted in 13 ORs significantly greater or less than unity. Multiple
testing and small numbers mean these results could potentially be
explained by chance. However, interpretation of their significance
will depend on the existence of a prior hypothesis, biological
plausibility, the presence of a ‘dose–response’ and consistency
with other published reports of the same effect. The results from
the present study are described by subgroup and discussed in the
context of findings from other studies. A study of neonatal expo-
sure to Vitamin K is already published (McKinney et al, 1998).
Leukaemias and acute lymphoblastic leukaemia
One striking finding was the significant deficit of neonatal infections
for children who later developed ALL, applying especially to those
diagnosed between the ages of 0 and 4 years. Protection appears to be
most prominent for children diagnosed in the ‘childhood peak’ of
ALL, which mainly comprises the common pre-B-cell immuno-
phenotype. The negative association for neonatal infections supports
the hypothesis proposed by Greaves and Alexander (1993). This
postulates that a lack of exposure to infections in infancy and
immunological isolation increases the risk of common ALL, because
in the absence of early exposure the immune system may remain
‘unprogrammed’ and unable to respond appropriately later in life
(Greaves, 1997).
The restriction of the protective effect of infections to the young
leukaemias is unlikely to be artefactual. The differential frequency
of infections by age group in the ALLs is clearly not present in the
CNS group, although it is seen to a lesser extent in the small
lymphoma group and the heterogeneous ‘other solid tumours’.
A significant excess of control children had ‘any infection’,
mainly accounted for by skin infections. Clinical observations of
an infection were accompanied by confirmed positive laboratory
swab tests for approximately half of all the infections for both
cases and controls.
To address the issue of confounding, adjustment was made for
the other significant variables and those considered to an appro-
Table 4 Odds ratios (OR), 95% confidence intervals (CI) and numbers of exposed cases (ca) and controls (co) for neonatal risk factors by diagnostic subgroup
Factor Categorya Total Acute lymphoblastic Other solid
leukaemias leukaemia (subset) Lymphomas CNS tumours tumours
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Ca 144, Co 271 Ca 124, Co 236 Ca 45, Co 82 Ca 75, Co 133 Ca 126, Co 230
Gestation (weeks) 38–42 vs < 38 1.00 (0.49–2.03) 0.93 (0.44–1.97) 0.51 (0.13–1.93) 1.00 (0.42–2.40) 0.93 (0.43–2.01)
14, 26 12, 24 4, 12 9, 16 12, 24
Birthweight (g) < 2500 1.84 (0.67–5.04) 1.52 (0.52–4.43) 2.03 (0.42–9.75) 1.36 (0.35–5.26) –
9, 10 7, 10 4, 4 4, 5 5, 11
2500–3499 1.00 1.00 1.00 1.00 1.00
74, 149 64, 131 21, 40 39, 69 70, 119
³ 3500 1.12 (0.73–1.73) 1.17 (0.74–1.85) 0.99 (0.43–2.28) 0.99 (0.54–1.83) 0.84 (0.54–1.33)
60, 112 52, 95 19, 38 32, 58 51, 100
Admitted to special care No vs yes 1.53 (0.93–2.50) 1.56 (0.93–2.62) 0.70 (0.29–1.69) 0.85 (0.38–1.89) 1.07 (0.61–1.90)
Unit 40, 58 36, 52 10, 22 12, 24 28, 49
Jaundice No vs yes 0.79 (0.51–1.20) 0.77 (0.49–1.21) 0.67 (0.32–1.44) 0.87 (0.48–1.58) 1.04 (0.66–1.63)
49, 109 44, 100 20, 44 30, 58 46, 82
Initially breastfed No vs yes 0.96 (0.62–1.49) 0.92 (0.58–1.47) 0.86 (0.41–1.84) 1.39 (0.72–2.67) 0.73 (0.44–1.19)
52, 99 44, 87 18, 36 31, 47 38, 82
Neonatal Infections No vs yes 0.62 (0.34–1.11) 0.49d (0.26–0.95) 1.18 (0.50–2.80) 0.91 (0.38–2.15) 0.97 (0.55–1.71)
Any 19, 55 15, 52 10, 15 12, 23 22, 43
Conjunctivitis No vs yes 0.76 (0.38–1.51) 0.63 (0.29–1.36) 1.43 (0.55–3.68) 0.81 (0.30–2.21) 0.56 (0.27–1.16)
13, 33 10, 30 9, 11 7, 15 11, 34
Skin No vs yes 0.20b (0.05–0.87) 0.20e (0.05–0.87) – 0.40 (0.08–2.10) 3.24f (1.35–7.78)
2, 19 2, 19 2, 4 2, 8 14, 9
Apgar at 1 min 7+ 1.00 1.00 1.00 1.00 1.00
111, 225 97, 195 38, 67 65, 109 106, 185
4–6 1.81c (1.03–3.19) 1.79 (0.99–3.24) 0.63 (0.19–2.09) 0.66 (0.22–1.96) 0.66 (0.30–1.44)
27, 30 24, 27 4, 10 6, 15 10, 27
1–3 – – – – –
4, 8 2, 7 0, 3 3, 4 5, 9
Problems at birth
Complications of cord No vs yes 1.36 (0.69–2.68) 1.10 (0.52–2.33) 1.84 (0.46–7.41) 1.21 (0.43–3.44) 0.61 (0.29–1.26)
17, 23 13, 22 4, 4 7, 10 11, 31
Cyanosis No vs yes 0.57 (0.26–1.24) 0.53 (0.23–1.22) 1.90 (0.57–6.39) 0.48 (0.15–1.51) 0.87 (0.41–1.83)
9, 28 8, 26 6, 6 4, 15 11, 23
Vomiting No vs yes 0.63 (0.22–1.77) 0.63 (0.20–1.97) 1.56 (0.24–10.1) 1.08 (0.28–4.18) 1.36 (0.57–3.26)
5, 15 4, 12 3, 4 5, 7 9, 13
Cephalohaematoma No vs yes 0.88 (0.34–2.33) 0.77 (0.26–2.34) 1.79 (0.36–8.97) 1.15 (0.32–4.14) –
scalp injury 7, 15 5, 12 3, 3 4, 6 1, 8
Birth asphyxiation No vs yes 2.44g (1.15–5.20) 2.41h (1.05–5.52) 1.79 (0.36–8.97) – 1.21(0.52–2.80)
16, 13 13, 11 3, 3 3, 4 10, 15
aReference category stated first. bP = 0.032; cP = 0.038; dP = 0.034; eP = 0.032; fP = 0.008; gP = 0.020; hP = 0.039.Perinatal risks for childhood leukaemia and cancer 1849
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priate proxy for social class, i.e. deprivation and maternal school-
leaving age. The results remained unaffected and therefore unex-
plained by social class, which is perhaps not surprising as neither
deprivation nor school-leaving age are significant in the univariate
analysis. If lower social class is related to higher infectious expo-
sure the general direction of the results are not supportive of the
infections hypothesis. Caesarean delivery is likely to result in
reduced exposure to infection compared to vaginal delivery, but
the neonatal infections remained independent of this potential
confounder.
A negative association was observed for maternal use of topical
antifungals, primarily pessaries prescribed for vaginal
thrush/candidiasis, for the all leukaemia category. This was not
explained by maternal age, a possible indicator of increased levels
of hospital care and, consequently, increased frequency of
recording. The presence of candida may act as a marker for other
vaginal infections (Cotch et al, 1998) and increase exposure to
infections in vaginally delivered babies. Adjustment for type of
delivery did not alter the OR for antifungal medication, which
provides limited support for the theory that exposure to infectious
agents reduces the risk of childhood ALL.
Few other studies have reported on neonatal or early infections.
Exposure to specific viral infections under 6 months of age, as
reported at interview, has been noted to increase the risk of
leukaemia/lymphoma (McKinney et al, 1987). This is in contrast
to a Dutch study from a postal questionnaire showing that children
with leukaemia experienced fewer infections in the first year of
life (van Steensel-Moll et al, 1986).
Reports of increased risk of leukaemia for first-born children
have been inconsistent (Fasal et al, 1971; Shaw et al, 1984; Roman
et al, 1997; Westergaard et al, 1997). Our results for neither first
pregnancies nor first live births were statistically significant for
leukaemia (or ALL). Children born first in a family are likely to
have lower exposure to infections than those of a higher birth
order and our findings of lowered risk for not being first born are
weakly supportive of the delayed infectious exposure hypothesis.
The following observations summarize the evidence consistent
with the prior hypothesis of a low frequency of infections
increasing risk. Significantly reduced ORs for neonatal infections,
particularly in the 0 to 4-year-olds, and the lowered risk for anti-
fungal use in pregnancy are the strongest signals of support, with
parity providing weaker corroboration.
No association for all leukaemias or ALL was found with high
birthweight, in common with some (McKinney et al, 1987; Golding
et al, 1990; Zack et al, 1991; Roman et al, 1997), but not all studies
(Fasal et al, 1971; Daling et al, 1984; Shu et al, 1988; Kaye et al,
1991; Cnattingius et al, 1995; Ross et al, 1996; Westergaard et al,
1997), although high birthweight has been linked to acute myeloid
leukaemia (Roman et al, 1997; Westergaard et al, 1997) and
children diagnosed with cancers under 2 years (Yeazel et al, 1997).
Ross and colleagues (Ross et al, 1996) argue for a biological mech-
anism involving insulin-like growth factor (IGF-1) to explain risks
correlated with high birthweight.
Perinatal hypoxia was not associated with childhood leukaemia
but was linked to ‘other and unspecified solid tumours’ in a
Swedish birth registry study (Forsberg and Kallen, 1990). This
contrasts with the present results where both poor Apgar scores
and birth asphyxia recorded in the notes raised the risk for
leukaemias. The reason for these associations is not clear and it is
notable the effect did not persist to the Apgars at 5 min.
Childhood leukaemia and maternal use of drugs in pregnancy
and during labour have been extensively studied with links
observed for the following labour drugs – inhaled nitrous oxide
anaesthesia (Zack et al, 1991), narcotic analgesia (McKinney et al,
1987; Gilman et al, 1989; Golding et al, 1990) and sedatives
and tranquillizers in pregnancy (McWhirter and Chant, 1990). The
Table 5 Frequencies, odds ratios (OR) and 95% confidence intervals (CI) of neonatal infections for the leukaemias and acute lymphoblastic leukaemias by
age
Total leukaemias Acute lymphoblastic leukaemias
(n = 144) (n = 124)
Infection Age group Cases Controls OR Cases Controls OR
n (%) n (%) (95% CI) n (%) n (%) (95% CI)
Any (1 or more) 0–4 10 (11.8) 39 (23.6) 0.40a 9 (11.7) 38 (25.3) 0.35b
(0.17–0.90) (0.15–0.83)
5–14 9 (15.3) 16 (15.1) 1.10 6 (12.8) 14 (16.3) 0.85
(0.47–2.59) (0.32–2.27)
Respiratory tract 0–4 0 1 – 0 1 –
5–14 0 1 – 0 1 –
Gastrointestinal tract 0–4 0 0 – 0 0 –
5–14 0 1 – 0 1 –
Fungal 0–4 1 3 – 1 3 –
5–14 1 0 – 0 0 –
Skin 0–4 2 (2.4) 14 (8.5) 0.27 2 (2.6) 14 (9.3) 0.27
(0.06–1.21) (0.06–1.21)
5–14 0 5 – 0 5 –
Conjunctivitis 0–4 7 (8.2) 23 (13.9) 0.55 6 (7.8) 22 (14.7) 0.47
(0.22–1.40) (0.17–1.30)
5–14 6 (10.2) 10 (9.4) 1.22 4 (8.5) 8 (9.3) 1.00
(0.43–3.47) (0.30–3.32)
Otherc 0–4 1 3 – 1 3 –
5–14 3 1 – 2 1 –
aP = 0.027; bP = 0.017; cIncludes ICD-10 P36 Bacterial sepsis of newborn and P39.9 Infection specific to the perinatal period, unspecified.1850 PA McKinney et al
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present study lent little support to the concept of transplacental
leukaemogenesis effected by maternal drug use.
Lymphomas
The finding that significantly more mothers of control children
received ultrasound scans is not supported by other published
literature (McKinney et al, 1987; Shu et al, 1994). The majority
of examinations were conducted in the second trimester and
increasing numbers of scans conferred greater protection. The
explanation for this is unlikely to be biological and ultrasound
examinations may well be markers of other exposures. The sepa-
rate ORs for Hodgkin’s disease and non-Hodgkin’s lymphoma are
both less than unity, but neither are statistically significant. A
recent study of non-Hodgkin’s lymphoma revealed few maternal
or perinatal risk factors (Adami et al, 1996).
Central nervous system tumours
The only maternal or neonatal factor associated with risk of devel-
oping a CNS tumour was an inverse association with use of
antacids during labour. The absence of any other significant risks
is consistent with the findings of McCredie et al (1994a, 1994b).
No association was found for anti-nausea medication during preg-
nancy, thus failing to support the findings from an American study
of children with astrocytomas (Kuijten et al, 1990). N-nitrosatable
drugs have been postulated as transplacental carcinogens, but
neither this or another study (Carozza et al, 1995) found an
elevated risk. Use of narcotic analgesics during pregnancy and
labour have been linked specifically to childhood CNS tumours
(Linet et al, 1996), but our study results were non-significant.
Neonatal infections and neonatal distress observed as increasing
risk by Linet et al (1996) had non-significant ORs close to unity in
the current study.
Other solid tumours
The analysis of a solid tumour group was pragmatic, as, although
subtypes within this subgroup may have differing aetiologies, the
consequence of further subdivision would have been unacceptably
low power. Some infections in pregnancy are known to have terato-
genic consequences; for example, rubella and cytomegalovirus, but
the search for in-utero infections which may be transplacental
carcinogens has been unsuccessful. The current study has shown a
significantly raised risk of infections in pregnancy for the other
solid tumours, accounted for by the respiratory tract. Interpretation
is difficult as the confidence intervals are wide, particularly for the
respiratory tract infections, and the infections relate to a mixed
group of tumour types, none of which predominated, indicating a
causal link is improbable.
Neonatal skin infections were associated with a significantly
increased risk for the other solid tumours. This was unsupported
by other results in this exposure category as the finding was not
restricted to any particular tumour type and the OR for ‘any
neonatal infection’ was in the opposite direction.
CONCLUSIONS
Overall, few specific maternal or neonatal risks were statistically
significant for individual disease subgroups. This may represent
a real effect implying that early exposures are not important
determinants of risk or simply reflect a lack of statistical power.
The possibility remains of there being risks associated with factors
which either are unmeasured or were represented by insufficient
numbers in the current study; for example, maternal ingestion of a
specific drug. The most notable finding was a negative association
with neonatal infections and leukaemia and ALL. This supports
the concept of infectious exposure in early life conferring protec-
tion against these malignancies. The combination of data from this
and other similar population-based studies will improve power
and, crucially, improved size will permit examination by diag-
nostic groups that are more clearly defined both at the histological
and molecular level.
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